The GLP is committed to full transparency. Download and review our just-released 2019 Annual Report.

23andMe thrives despite long-running conflicts with FDA

| | October 18, 2017

[23andMe CEO Anne] Wojcicki set out to disrupt the health-care industry in 2006. Her goal was to put sophisticated DNA analyses into the hands of consumers, giving them information about health, disease and ancestry, and allowing the company to sell access to the genetic data to fuel research. But in 2013, that vision hit a snag. Wojcicki didn’t think she needed regulatory approval to provide information about her customers’ health risks. The US Food and Drug Administration (FDA) disagreed, and ordered the company to stop.

Wojcicki aimed to attract millions of customers by selling an inexpensive test that would reveal genetic predispositions for dozens of traits. It would provide disease risks, but also genetic propensity for baldness, obesity and trivial features such as earwax consistency.

23andme is still barred from giving customers lots of available information, such as whether they carry gene variants that raise their risk for certain cancers or that predict how well certain medications will work. Before the FDA lockdown, it had been providing information on hundreds of health conditions.

Most scientists no longer see 23andme as a frivolous undertaking. The ability to recruit two million customers, and potentially many more, has been a huge draw, and researchers are lining up to collaborate with the company.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post: The rise and fall and rise again of 23andMe

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend